Digestive tract involvement in systemic sclerosis

Autoimmunity Reviews

Volumn 11, Issue 1, 2011, Pages 68-73

  Tiev, Kiet Phong ^a   Cabane, Jean ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; CLINICAL FEATURE; COLON DISEASE; COLON DIVERTICULOSIS; DIGESTIVE SYSTEM; ESOPHAGUS DISEASE; FECES INCONTINENCE; GASTROESOPHAGEAL REFLUX; HUMAN; ILEUS; LIVER HYPERPLASIA; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SKIN FIBROSIS; SMALL INTESTINE DISEASE; STOMACH ANTRUM VASCULAR ECTASIA; STOMACH EMPTYING; STOMACH PARESIS; SYSTEMIC SCLEROSIS; TEMPOROMANDIBULAR JOINT DISORDER; XEROSTOMIA;

DIGESTIVE SYSTEM; DIGESTIVE SYSTEM DISEASES; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 80855148837     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.06.002     Document Type: Review

References (55)

1. Czompoly T., Simon D., Czirjak L., Nemeth P. Anti-topoisomerase I autoantibodies in systemic sclerosis. Autoimmun Rev 2009, 8:692-696.
2. Ranque B., Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010, 9:A311-A318.
3. Ebert E.C. Gastric and enteric involvement in progressive systemic sclerosis. J Clin Gastroenterol 2008, 42:5-12.
4. Sjogren R.W. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994, 37:1265-1282.
5. Forbes A., Marie I. astrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology 2009, 48(Suppl 3):iii36-iii39.
6. Lock G., Holstege A., Lang B., Scholmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol 1997, 92:763-771.
7. Steen V.D., Medsger T.A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000, 43:2437-2444.
8. D'Angelo W.A., Fries J.F., Masi A.T., Shulman L.E. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969, 46:428-440.
9. Sallam H., McNearney T.A., Chen J.D. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 2006, 23:691-712.
10. Nietert P.J., Mitchell H.C., Bolster M.B., Curran M.Y., Tilley B.C., Silver R.M. Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol 2005, 32:51-57.
11. Gliddon A.E., Dore C.J., Maddison P.J. Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis. Arthritis Rheum 2006, 55:473-479.
12. Sanchez-Castanon M., de las Heras-Castano G., Lopez-Hoyos M. Autoimmune pancreatitis: an underdiagnosed autoimmune disease with clinical, imaging and serological features. Autoimmun Rev 2010, 9:237-240.
13. Dreiling D.A., Soto M.J. The pancreatic involvement in disseminated "collagen" disorders. Studies of pancreatic secretion in patients with scleroderma and Sjogren's "disease". Am J Gastroenterol 1976, 66:546-553.
14. Marie I., Ducrotte P., Antonietti M., Herve S., Levesque H. Watermelon stomach in systemic sclerosis: its incidence and management. Aliment Pharmacol Ther 2008, 28:412-421.
15. Manetti M., Neumann E., Milia A.F., Tarner I.H., Bechi P., Matucci-Cerinic M., et al. Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients. Arthritis Rheum 2007, 56:3442-3447.
16. Manetti M., Neumann E., Muller A., Schmeiser T., Saar P., Milia A.F., et al. Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. Arthritis Rheum 2008, 58:2866-2873.
17. Singh J., Mehendiratta V., Del Galdo F., Jimenez S.A., Cohen S., DiMarino A.J., et al. Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. Am J Physiol 2009, 297:G1206-G1213.
18. Marie I., Cailleux N., Levesque H. Watermelon stomach and systemic sclerosis: localization of digestive system involvement?. Arthritis Rheum 1996, 39:1439.
19. Rigamonti C., Shand L.M., Feudjo M., Bunn C.C., Black C.M., Denton C.P., et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006, 55:388-394.
20. Vincent C., Agard C., Barbarot S., N'Guyen J.M., Planchon B., Durant C., et al. Orofacial manifestations of systemic sclerosis: a study of 30 consecutive patients. Rev Méd Interne 2009, 30:5-11.
21. Ntoumazios S.K., Voulgari P.V., Potsis K., Koutis E., Tsifetaki N., Assimakopoulos D.A. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum 2006, 36:173-181.
22. Marie I., Ducrotte P., Denis P., Hellot M.F., Levesque H. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther 2006, 24:1593-1601.
23. Lock G., Zeuner M., Lang B., Hein R., Scholmerich J., Holstege A. Anorectal function in systemic sclerosis: correlation with esophageal dysfunction?. Dis Colon Rectum 1997, 40:1328-1335.
24. Ebert E.C. Esophageal disease in scleroderma. J Clin Gastroenterol 2006, 40:769-775.
25. Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med 2009, 361:2548-2556.
26. Recht M.P., Levine M.S., Katzka D.A., Reynolds J.C., Saul S.H. Barrett's esophagus in scleroderma: increased prevalence and radiographic findings. Gastrointest Radiol 1988, 13:1-5.
27. Wipff J., Allanore Y., Soussi F., Terris B., Abitbol V., Raymond J., et al. Prevalence of Barrett's esophagus in systemic sclerosis. Arthritis Rheum 2005, 52:2882-2888.
28. Savarino E., Bazzica M., Zentilin P., Pohl D., Parodi A., Cittadini G., et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009, 179:408-413.
29. Tonini M., De Giorgio R., De Ponti F. Progress with novel pharmacological strategies for gastro-oesophageal reflux disease. Drugs 2004, 64:347-361.
30. Marie I., Levesque H., Ducrotte P., Denis P., Hellot M.F., Benichou J., et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol 2001, 96:77-83.
31. Dull J.S., Raufman J.P., Zakai M.D., Strashun A., Straus E.W. Successful treatment of gastroparesis with erythromycin in a patient with progressive systemic sclerosis. Am J Med 1990, 89:528-530.
32. Maganti K., Onyemere K., Jones M.P. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003, 98:259-263.
33. Watson M., Hally R.J., McCue P.A., Varga J., Jimenez S.A. Gastric antral vascular ectasia (watermelon stomach) in patients with systemic sclerosis. Arthritis Rheum 1996, 39:341-346.
34. Shibukawa G., Irisawa A., Sakamoto N., Takagi T., Wakatsuki T., Imamura H., et al. Gastric antral vascular ectasia (GAVE) associated with systemic sclerosis: relapse after endoscopic treatment by argon plasma coagulation. Intern Med 2007, 46:279-283.
35. Greydanus M.P., Camilleri M. Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. Gastroenterology 1989, 96:110-115.
36. Marie I., Levesque H., Ducrotte P., Denis P., Benichou J., Hellot M.F., et al. Manometry of the upper intestinal tract in patients with systemic sclerosis: a prospective study. Arthritis Rheum 1998, 41:1874-1883.
37. Marie I., Ducrotte P., Denis P., Hellot M.F., Levesque H. Outcome of small-bowel motor impairment in systemic sclerosis-a prospective manometric 5-yr follow-up. Rheumatology 2007, 46:150-153.
38. Gasbarrini A., Lauritano E.C., Gabrielli M., Scarpellini E., Lupascu A., Ojetti V., et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 2007, 25:237-240.
39. Marie I., Ducrotte P., Denis P., Menard J.F., Levesque H. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology 2009, 48:1314-1319.
40. Parodi A., Sessarego M., Greco A., Bazzica M., Filaci G., Setti M., et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 2008, 103:1257-1262.
41. Nikou G.C., Toumpanakis C., Katsiari C., Charalambopoulos D., Sfikakis P.P. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol 2007, 13:119-123.
42. Govoni M., Muccinelli M., Panicali P., La Corte R., Nuccio Scutellari P., Orzincolo C., et al. Colon involvement in systemic sclerosis: clinical-radiological correlations. Clin Rheumatol 1996, 15:271-276.
43. Schuffler M.D., Rohrmann C.A., Chaffee R.G., Brand D.L., Delaney J.H., Young J.H. Chronic intestinal pseudo-obstruction. A report of 27 cases and review of the literature. Medicine 1981, 60:173-196.
44. Ebert E.C., Ruggiero F.M., Seibold J.R. Intestinal perforation. A common complication of scleroderma. Dig Dis Sci 1997, 42:549-553.
45. Cooper Z.R., Rose S. Fecal incontinence: a clinical approach. Mt Sinai J Med 2000, 67:96-105.
46. Heyt G.J., Oh M.K., Alemzadeh N., Rivera S., Jimenez S.A., Rattan S., et al. Impaired rectoanal inhibitory response in scleroderma (systemic sclerosis): an association with fecal incontinence. Dig Dis Sci 2004, 49:1040-1045.
47. Engel A.F., Kamm M.A., Talbot I.C. Progressive systemic sclerosis of the internal anal sphincter leading to passive faecal incontinence. Gut 1994, 35:857-859.
48. Leighton J.A., Valdovinos M.A., Pemberton J.H., Rath D.M., Camilleri M. Anorectal dysfunction and rectal prolapse in progressive systemic sclerosis. Dis Colon Rectum 1993, 36:182-185.
49. Kenefick N.J., Vaizey C.J., Nicholls R.J., Cohen R., Kamm M.A. Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut 2002, 51:881-883.
50. Jaffin B.W., Chang P., Spiera H. Fecal incontinence in scleroderma. Clinical features, anorectal manometric findings, and their therapeutic implications. J Clin Gastroenterol 1997, 25:513-517.
51. Watt F.E., James O.F., Jones D.E. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. Qjm 2004, 97:397-406.
52. Corpechot C., Carrat F., Bahr A., Chretien Y., Poupon R.E., Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005, 128:297-303.
53. Corpechot C., Carrat F., Bonnand A.M., Poupon R.E., Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000, 32:1196-1199.
54. Norman G.L., Bialek A., Encabo S., Butkiewicz B., Wiechowska-Kozlowska A., Brzosko M., et al. Is prevalence of PBC underestimated in patients with systemic sclerosis?. Dig Liver Dis 2009, 41:762-764.
55. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010, 52:745-758.